Previous 10 | Next 10 |
Iovance Biotherapeutics, Inc. (IOVA) Q2 2019 Results Earnings Conference Call August 01, 2019, 04:30 PM ET Company Participants Timothy Morris - CFO Maria Fardis - President and CEO Friedrich Finckenstein - Chief Medical Officer Conference Call Participants Mark Breidenbach...
Iovance Biotherapeutics (NASDAQ: IOVA ): Q2 GAAP EPS of -$0.38 misses by $0.09 . More news on: Iovance Biotherapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
- Regulatory submission for LN-145 in advanced cervical cancer expected in the second half of 2020 - - Company to host conference call at 4:30 p.m. EDT today - SAN CARLOS, Calif., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology c...
SAN CARLOS, Calif., July 26, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its second quarter 2019...
Biotech Pulse The first half of 2019 had a little bit of everything for biotechs. After a punishing close to last year, with the Nasdaq Biotechnology Index ( IBB ) down 10% for 2018, biotechs rebounded during the first quarter along with the broader market. However, the second quarter provid...
SAN CARLOS, Calif., July 18, 2019 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced the appointment of Friedrich Graf Finckenst...
by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...
Listen and subscribe to the Marketplace Roundtable on these podcast platforms: iTunes/Apple Podcasts Spotify Stitcher By Jonathan Liss On the latest Marketplace Roundtable Podcast, Bhavneesh Sharma sits down to discuss his background as a practicing M.D...
Iovance Biotherapeutics (NASDAQ: IOVA ) perks up 4% premarket on light volume in reaction to positive developments on the regulatory pathway for Fast Track- and Breakthrough Therapy-tagged LN-145. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stocks on ...
Iovance Biotherapeutics (NASDAQ: IOVA ) perks up 4% premarket on light volume in reaction to positive developments on the regulatory pathway for Fast Track- and Breakthrough Therapy-tagged LN-145. More news on: Iovance Biotherapeutics, Inc., Healthcare stocks news, Stocks on ...
News, Short Squeeze, Breakout and More Instantly...
Iovance Biotherapeutics Inc. Company Name:
IOVA Stock Symbol:
NASDAQ Market:
Iovance Biotherapeutics Inc. Website:
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 ...
2024-04-28 14:44:00 ET There's a lot of excitement around Iovance Biotherapeutics (NASDAQ: IOVA) as its shares are up over 40% year-to-date. Investors and analysts both see even more upside for this mid-cap biotech stock in the long run. Today, however, the company remains deepl...
SAN CARLOS, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biote...